Project Grant R35CA283888
Award Date
9/9/24
Completion Date
8/31/31
Dollars Obligated
$932K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $140,433 to The Leland Stanford Junior University to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a novel "Programmable Antibody-mediated Cellular Knock-in of T cells" (PACK-IT) system. The goal is to develop a more effective and accessible CAR-T cell therapy for B-cell malignancies by eliminating the ex vivo manufacturing process. The project...
This federal Project Grant award of $207,900 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports research at The Leland Stanford Junior University (Stanford University) to develop a three-cell synthetic immunotherapy system. The goal is to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $1,390,720 to The Leland Stanford Junior University (Stanford University) to develop an optimized chimeric antigen receptor (CAR) T-cell therapy targeting cerebroglycan (GPC2) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The key objectives are to: 1) Define the optimal approach to overexpress the transcription factor cJun in...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, supports research to identify genes and pathways that are suppressed during early tumor development, enabling cancers to evade immune surveillance. The $901,205 award, which began on Jul 3, 2025 and runs through Jun 30, 2032, will leverage genetically engineered mouse models and advanced genomic and spatial...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $170,376 to The Leland Stanford Junior University to develop a rapid, label-free, and cost-effective technique for quantifying chimeric antigen receptor (CAR) T cells in patient blood samples using surface enhanced Raman spectroscopy (SERS) and machine learning. The project aims to optimize SERS methods for analyzing immune cell spectra, develop machine learning...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $640,522 to The Leland Stanford Junior University to conduct research aimed at identifying microbial microproteins that can modulate macrophage function and potentially enhance cancer immunotherapy response. The key objectives are to: 1) determine the molecular mechanisms by which two specific microbial microproteins modulate macrophage polarization, 2) screen a large library of candidate...
This $135,594 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells, with a focus on aggressive leukemias driven by mixed-lineage leukemia (MLL) gene translocations. The research will involve organic synthesis, pharmacological assays, chromatin mechanism studies, cellular model...
This $113,147 federal Project Grant award was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to The Leland Stanford Junior University. The grant will fund a 5-year career development program for Dr. Chris McGinnis to prepare him for an independent research career in cancer immunology, focusing on studying tumor-immune interactions during metastasis. The key objectives are to: 1) Use longitudinal single-cell RNA sequencing to uncover novel mechanisms of...